GLP-1 Monthly Cost: 2026 Brand-by-Brand Breakdown

Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026

Key Takeaways

• GLP-1 therapy in 2026 can cost anywhere from $0–$50 per month with strong insurance support to more than $1,000 per month at full list price.
• Brand-name drugs such as Wegovy, Ozempic, Zepbound, and Mounjaro list between $1,028 and $1,349 per month, while manufacturer self-pay programs and savings cards often bring real monthly costs down to roughly $25–$499.
• Some Medicare beneficiaries qualify for the GLP-1 Bridge program at $50 per month, and many commercially insured patients with savings cards pay as little as $25 per month.
• Upcoming 2027 list-price cuts and lower-cost oral options, including the $149 starter-dose oral choices mentioned later, create more affordable paths for long-term treatment.
• Patients who want a tailored GLP-1 or peptide plan can schedule a consultation with Mirror Plastic Surgery to review safe, medically supervised options.

GLP-1 Monthly Cost Comparison: Brand-By-Brand Breakdown

Most brand-name GLP-1 list prices cluster around $1,000–$1,350 per month, while manufacturer self-pay and savings programs can cut that to the low hundreds. The table below shows how cash prices, typical insured copays, and the lowest legitimate self-pay options compare for each drug.

Drug	Typical Cash Price (No Insurance)	With Commercial Insurance (Typical Copay)	Cheapest Legitimate Self-Pay Option
Wegovy (semaglutide injection)	~$1,349/month list price	$25–$100 with savings card	$199/month first 2 fills (NovoCare), then $349
Ozempic (semaglutide injection)	~$1,028/month list price	$25–$100 with savings card	$199/month first 2 fills (NovoCare), then $349–$499
Zepbound (tirzepatide injection)	~$1,086/month list price	$25–$100 with savings card	$299–$449/month (LillyDirect vials)
Mounjaro (tirzepatide injection)	~$1,112/month list price	$25/month with savings card (T2D coverage required)	No flat-rate self-pay program; ~$1,112 cash
Oral Wegovy (semaglutide tablet)	~$1,349/month list price	$25–$100 with savings card	$149/month (1.5 mg, NovoCare)
Foundayo (orforglipron tablet)	~$649/month list price	$25–$100 with savings card	$149/month (0.8 mg, LillyDirect)

Wegovy’s published U.S. list price is $1,349.02 for a 30-day supply, the same across all doses of both the injection and the tablet. However, NovoCare’s self-pay channel charges far less: $349/month for standard Wegovy injectable pen doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) after a limited-time $199/month offer for the first two months, with Wegovy HD (7.2 mg) at about $399/month. The oral version is even cheaper, and its 1.5 mg starter dose at $149/month makes it the lowest-priced branded GLP-1 in 2026.

Ozempic’s list price is approximately $1,028 per month. NovoCare’s standard self-pay pricing is $349 per month for the 0.25 mg, 0.5 mg, or 1 mg doses and $499 per month for the 2 mg dose, after a limited-time $199-per-month offer for new patients for the first two months through December 31, 2026. Ozempic is FDA-approved for type 2 diabetes, not weight loss, so off-label use for obesity often faces tougher insurance and savings-card rules.

Zepbound’s list price is $1,086.37 for a 28-day supply. Through LillyDirect’s Zepbound Self Pay Journey Program, self-pay prices are $299/month (2.5 mg), $399/month (5 mg), and $449/month (7.5–15 mg) when refills occur within 45 days.

Mounjaro’s list price is $1,112.16 per fill. Eli Lilly offers manufacturer self-pay savings for uninsured patients, as noted on its official pricing page, but there is no flat-rate LillyDirect cash-pay program similar to Zepbound’s. Foundayo (orforglipron), the FDA-approved oral GLP-1 cleared on April 1, 2026, lists at $649/month with LillyDirect self-pay pricing from $149/month for 0.8 mg to $349/month for the 14.5 mg and 17.2 mg doses.

A major price reset is on the horizon. Effective January 1, 2027, Novo Nordisk will cut the list price of Wegovy, Ozempic, and Rybelsus to $675 per month, which represents about a 50% reduction for Wegovy. At the same time, CMS’s negotiated IRA Maximum Fair Prices for 2027 set Ozempic at $276.78 per package for a 4 mg/3 mL pen and Wegovy at $385.63 per package for a 2.4 mg four-pen box. Current 2026 prices still apply until those changes take effect.

With Insurance vs. Without Insurance: Calculating Your Real Out-of-Pocket Cost

List price tells only part of the story. Your monthly bill depends far more on your insurance status and access to savings programs, which usually fall into three common scenarios.

Scenario A — Commercial Insurance With Coverage and a Savings Card: If your plan covers the drug, a manufacturer savings card from NovoCare (Wegovy/Ozempic) or LillyDirect (Zepbound/Mounjaro) can drop your copay to as low as $25/month. Novo Nordisk’s Ozempic savings card, for example, can reduce copays to $25/month for eligible commercially insured patients, with a maximum savings of $100 off a 1‑month supply. For most people with qualifying commercial coverage, this is the lowest realistic monthly cost.

Scenario B — Commercial Insurance, No Weight-Loss Coverage: Many plans exclude obesity drugs entirely. If your denial stems from prior authorization or medical-necessity criteria, an appeal can still succeed, but when a plan hard-excludes weight-loss drugs, cash-pay paths are usually faster. Coverage for weight-loss GLP-1s has tightened, and only about 4% of commercially insured patients have unrestricted Zepbound coverage in 2026.

Scenario C — No Insurance: Without coverage, list prices apply unless you use manufacturer self-pay programs. As of September 2026, self-pay prices for brand GLP-1s range from $149 to $449 per month for select products and doses, such as the $149 oral starter options and Zepbound maintenance at $449, with some higher doses costing more. The same source notes that the TrumpRx.gov portal, launched February 5, 2026, lists entry self-pay prices like Wegovy pill at $149/month, Wegovy pen at $199/month for the first two fills of 0.25 mg and 0.5 mg (then $349/month), Ozempic pen at $199/month for the first two fills (then $349/month), and Zepbound vial at $299/month for the 2.5 mg starter dose.

Medicare and Medicaid: The Medicare GLP-1 Bridge, active from July 1, 2026 through December 31, 2027, gives eligible Part D beneficiaries a flat $50/month copay for Wegovy, Zepbound (KwikPen only), and Foundayo. This $50 payment does not count toward the plan deductible or annual out-of-pocket maximum. Medicaid coverage remains narrow: as of January 2026, only 13 state Medicaid fee-for-service programs cover GLP-1s for obesity treatment, and several states, including California, New Hampshire, Pennsylvania, and South Carolina, have removed coverage.

Patients who want help mapping these scenarios to their own coverage can meet with Dr. Akash at Mirror Plastic Surgery to review insurance, self-pay, and peptide-based options in one visit.

How to Save on GLP-1 Therapy: A Step-By-Step Checklist

This checklist walks you through the most reliable ways to bring your monthly GLP-1 cost down while staying within legitimate, medically supervised channels.

1. Check insurance coverage. Confirm whether your plan covers the specific drug for your diagnosis. If it does, ask your doctor to submit a prior authorization.
2. Apply a manufacturer savings card. If coverage exists, use the NovoCare savings card for Wegovy/Ozempic or the LillyDirect savings card for Zepbound/Mounjaro to reduce copays, often to $25/month. These cards exclude Medicare, Medicaid, VA, and TRICARE beneficiaries.
3. Compare manufacturer self-pay programs. If your plan does not cover the drug, compare NovoCare ($199–$499) and LillyDirect ($149–$449), and review pricing on the TrumpRx portal.
4. Explore patient assistance programs. Novo Nordisk’s Patient Assistance Program covers Ozempic for uninsured patients with household income at or below 200% of the federal poverty level (~$31,300 for a single person in 2026), though sources do not clearly define Wegovy criteria. Eli Lilly’s Lilly Cares program covers Mounjaro and, in some reports, Zepbound for patients at or below 400% of the federal poverty level, although Zepbound’s inclusion may vary by year.
5. Ask about oral GLP-1s. The $149 oral starter options described earlier often represent the lowest FDA-approved self-pay entry point.
6. Consider medically supervised compounded GLP-1s. Compounded semaglutide has a month‑1 median price of $197 (range $88–$299), and compounded tirzepatide a median of $239 (range $149–$470) across licensed telehealth providers. These savings only make sense when the prescription comes from a licensed, reputable provider who offers full medical supervision.
7. Use HSA or FSA funds. GLP-1 medications qualify for FSA and HSA use when prescribed for a documented condition such as obesity or type 2 diabetes. Paying with pre-tax dollars can cut your effective cost by roughly 20–40%, depending on your tax bracket.

After working through these steps, many people still have specific cost questions. The quick answers below address the most common ones.

What is the cheapest GLP-1 without insurance? As of mid‑2026, the lowest FDA-approved self-pay options are the 1.5 mg oral Wegovy starter and the 0.8 mg Foundayo starter, each at $149/month through manufacturer programs, with promotional end dates such as August 2026 for Wegovy and December 2026 for Foundayo. Compounded products can cost less but introduce added regulatory and safety concerns.

How do I get Ozempic for $25 a month? With a NovoCare savings card and qualifying commercial insurance that covers Ozempic, some patients pay as little as $25 per month. This pricing does not apply to Medicare, Medicaid, or uninsured patients.

New in 2026: Medicare Coverage, Price Drops, and the TrumpRx Portal

Several 2026 policy changes reshaped GLP-1 affordability for entire patient groups, beyond individual coupons or savings cards.

The Medicare GLP-1 Bridge launched July 1, 2026 and runs through December 31, 2027. Eligible Part D beneficiaries pay $50/month for Wegovy (injection or tablet), Zepbound (KwikPen only), or Foundayo. Clinical eligibility includes BMI thresholds and specific comorbidities such as heart failure, uncontrolled hypertension, certain chronic kidney diseases, pre-diabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People who already receive GLP-1s through Part D for type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease stay on their existing coverage and do not enter the Bridge. Doctors must send a prescription, wait for the pharmacy to request prior authorization, and then attest that the drug is paired with structured nutrition and physical activity consistent with the FDA label.

The TrumpRx.gov portal, live since February 5, 2026, centralizes manufacturer self-pay GLP-1 starting prices, which range from $149/month for select oral starters to $299/month for Zepbound, with some higher doses reaching $499/month. The portal links directly to NovoCare and LillyDirect and serves as a price-transparency tool rather than a prescribing platform.

Looking ahead to 2027, Novo Nordisk’s planned list-price cuts and CMS’s IRA Maximum Fair Prices will further reduce official pricing for Ozempic and Wegovy. These shifts expand access but still require a prescription and ongoing medical oversight.

The Hidden Costs: Labs, Appointments, and Memberships

Medication is only one line item in a GLP-1 budget. A realistic monthly plan also accounts for visits, labs, and any program fees.

• Initial consultation and follow-ups: Often $100–$300 per visit without insurance coverage.
• Lab tests: Typically $50–$200 per panel to track kidney, liver, and blood sugar markers, which guide safe dosing and adjustments.
• Telehealth memberships: About $30–$150/month with online services, depending on platform features and support level.

A program that bundles medication, labs, and follow-up care in a transparent package often delivers better long-term value than a low drug price with no supervision. At Mirror Plastic Surgery, Dr. Akash Chandawarkar’s concierge model includes detailed thyroid, liver, kidney, and hormone panels plus direct ongoing support, so patients understand the full cost of care from day one.

GLP-1 Vs. Retatrutide (GLP-3R): What’s The Future Of Cost-Effective Therapy?

Current GLP-1s dominate modern weight-loss care, yet both older drugs and emerging triple agonists shape the cost-effectiveness picture. Phentermine 37.5 mg, for example, can cost as little as $9.91–$16.85 per month with coupons, but its weight-loss results fall far below GLP-1 outcomes¹. In STEP 1, adults with overweight or obesity without diabetes lost about 14.9% of body weight on semaglutide 2.4 mg over 68 weeks, compared with 9.6% in STEP 2 among patients with type 2 diabetes¹.

The next major entrant is retatrutide, sometimes informally called “GLP-3R.” Retatrutide (LY3437943) is an investigational triple agonist that targets GLP-1, GIP, and glucagon receptors, and the nickname “GLP-3” does not refer to a real receptor. Legitimate access currently occurs only through registered clinical trials or Eli Lilly’s expanded access program for adults with refractory obesity and serious obesity-related complications who cannot enroll in a comparable trial. Eli Lilly plans to file for FDA approval in Q1 2027, with a decision expected in late 2027 or 2028. Industry analysts expect post-approval self-pay pricing via LillyDirect to mirror Zepbound’s model, with projected self-pay costs of about $299–$449/month for lower doses and a lowest-dose option near $349/month, while list prices may land between $1,000 and $1,500/month.

Mirror Plastic Surgery offers GLP-3R compounding within a supervised protocol as a newer-generation alternative that may provide broader metabolic benefits. For a deeper clinical comparison, see our guide on GLP-3R Vs GLP-1 Agonists: A Clinical Comparison Guide.

How to Talk to Your Doctor About GLP-1 Costs

Clear budget conversations help your provider design a plan that fits both your health goals and your finances. These questions keep the discussion focused and practical.

• “Is there a generic or oral version I can try first?”
• “Can you submit a prior authorization to my insurer?”
• “Do I qualify for a manufacturer savings card or patient assistance program?”
• “Is a compounded version appropriate for my health profile?”
• “What labs do I need before starting, and are they covered?”
• “Does your program bundle labs and follow-ups, or are those billed separately?”

A provider who answers these questions clearly and explains when a higher-priced option adds no benefit becomes a strong partner for long-term success. Patients who want this type of conversation can set up a GLP-1 cost and treatment consult with Dr. Akash.

Why Medical Supervision Matters: The True Cost of “Cheap” GLP-1s

Low advertised prices from online GLP-1 sellers can look appealing, yet the regulatory landscape in 2026 has shifted sharply. The FDA declared the semaglutide injection shortage resolved on February 21, 2025, and the tirzepatide shortage resolved in late 2024, so routine shortage-based compounding of copies is no longer allowed, although patient-specific compounding under Section 503A remains legal. On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products. By May 31, 2026, the agency had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. Any “cheap” online source that ignores these rules likely operates outside the law.

Gray market peptides sold online as “research use only” are illegal for human consumption when marketed or intended for human use. The FDA treats them as unapproved new drugs under the FD&C Act. They remain legal only when sold for genuine laboratory research. As endocrinologist Marc-Andre Cornier, MD, explains, “It’s not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there’s not a proper evaluation, there’s not a baseline, and there’s not proper supervision.”

Mirror Plastic Surgery provides a structured, medically supervised alternative. Dr. Akash Chandawarkar, a Harvard-educated, Johns Hopkins-trained, board-certified plastic surgeon with Stanford Biodesign training, personally oversees every peptide protocol. Each plan is tailored to your labs and physiology rather than a generic template. Peptides come from vetted sources with rigorous batch testing, and Dr. Akash remains available by text around the clock for ongoing support. The practice sees patients in person in Tampa and St. Petersburg and remotely across all 50 states. For more detail on this approach, visit our GLP-1 Medical Weight Loss Treatment in Tampa page.

Patients ready to pursue GLP-1 therapy safely and affordably can request a personalized peptide consultation with Mirror Plastic Surgery.

Frequently Asked Questions

What Is the Average Monthly Cost of GLP-1 Therapy?

Average monthly cost varies widely by insurance status and drug choice. With commercial insurance that covers the medication and a manufacturer savings card, some patients pay as little as $25/month, subject to eligibility rules, savings caps, and exclusion of government insurance. Medicare beneficiaries who qualify for the GLP-1 Bridge program pay $50/month. Uninsured patients using manufacturer self-pay programs such as NovoCare or LillyDirect typically pay $149–$499/month depending on drug and dose. Starter doses can be as low as $149, while maintenance doses reach about $499. These prices often depend on conditions such as introductory offers or refilling within 45 days, and higher doses can cost more when those conditions are not met. Without any program, branded GLP-1 list prices range from roughly $936 to $1,350 per month. The $149 oral starter options mentioned earlier currently represent the lowest FDA-approved self-pay entries, although those promotions are time-limited.

Is GLP-1 Covered by Insurance?

Coverage depends on the specific drug, diagnosis, and plan design. From 2024 through 2026, most commercial and Medicare Part D plans cover GLP-1 receptor agonists such as Ozempic, Mounjaro, and Rybelsus for type 2 diabetes with prior authorization. Coverage for weight-loss indications is far more limited, and only a small minority of commercially insured patients enjoy unrestricted access to drugs like Zepbound, as noted earlier. Prior authorization is almost always required. Medicaid coverage for obesity indications exists in only 13 states as of 2026. Medicare’s GLP-1 Bridge program offers $50/month access for qualifying beneficiaries who do not already receive GLP-1s through Part D for another condition.

Are There Cheaper Alternatives to Brand-Name GLP-1s?

Several lower-cost options exist. The $149 oral starter-dose programs described earlier are currently the least expensive FDA-approved choices. Compounded semaglutide from licensed 503A pharmacies has a median first-month cost of about $197, and the Weight Loss Rankings GLP-1 Compounded Pricing Index (August 2026) reports a median published price of $239/month for compounded tirzepatide across hundreds of providers, though availability depends on evolving FDA enforcement. Older medications such as phentermine can cost $10–$16/month with coupons but produce much less weight loss than GLP-1s. Any compounded option should come from a licensed provider who performs baseline evaluation and ongoing monitoring, not from unregulated online sellers.

Can I Get GLP-1s Without a Prescription?

All legitimate GLP-1 medications, whether brand-name or compounded, require a valid prescription from a licensed clinician. Buying “research use only” peptides online for personal injection or ingestion is illegal and risky, with no guarantee of purity, dose accuracy, or medical oversight. The FDA has increased enforcement against sellers of these products, including warning letters to telehealth companies that misrepresent compounded GLP-1s. Proper evaluation, baseline labs, and follow-up visits form the foundation of safe and effective therapy.

What Is GLP-3R And How Does It Compare To GLP-1?

Retatrutide (LY3437943) is an investigational triple agonist from Eli Lilly that targets GLP-1, GIP, and glucagon receptors, and the informal term “GLP-3” does not describe a real receptor. As of September 2026, retatrutide is not FDA-approved and is available only through registered clinical trials or Eli Lilly’s expanded access program for patients with refractory obesity. Early clinical data suggest greater average weight loss than current GLP-1s, with similar or higher rates of gastrointestinal side effects¹. Evidence on muscle preservation remains limited, and head-to-head comparisons with approved therapies are still emerging.

---

Read Next

• GLP-1 Side Effects Reviews: What 2025–2026 Patients Say
• GLP-1 Obesity Treatment: Evidence-Based Options (2026)
• GLP-1 Compounding Pharmacy Rules in 2026: What Changed
• GLP-1 Lab Monitoring: Baseline to Annual Schedules
• GLP-3R vs GLP-1 Agonists: A Clinical Comparison Guide